FY2030 Earnings Forecast for MetaVia Issued By HC Wainwright

MetaVia Inc. (NASDAQ:MTVA) – Equities researchers at HC Wainwright issued their FY2030 EPS estimates for shares of MetaVia in a research note issued to investors on Tuesday, January 6th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.65) per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Wall Street Zen upgraded MetaVia to a “sell” rating in a research report on Saturday, January 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $36.50.

MetaVia Price Performance

Shares of MetaVia stock opened at $8.38 on Thursday. MetaVia has a 1-year low of $6.05 and a 1-year high of $24.03. The company’s fifty day simple moving average is $8.76 and its 200-day simple moving average is $8.73. The stock has a market capitalization of $18.44 million, a PE ratio of -1.00 and a beta of 0.27.

MetaVia (NASDAQ:MTVA) last announced its earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.86) by $1.32.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.